Intercept Pharmaceuticals is undergoing a significant restructuring, which includes 146 layoffs across its operations. This move comes shortly after the withdrawal of its liver disease dr-g, Ocaliva, from the market. The layoffs are a direct consequence of the company's strategic re-evaluation and market adjustments. Affected employees will be impacted as the company realigns its operational focus in response to recent challenges. This restructuring aims to streamline Intercept's operations following the major product withdrawal.
https://www.fiercepharma.com/pharma/intercept-heels-ocaliva-withdrawal-restructures-146-layoffs